

Supplementary

Table S1 Adverse events in patients treated by gefitinib based on BALF liquid biopsy (n=40)

Adverse events (N=40)	All grades, n (%)	Grades \geq 3, n (%)
Skin eruption/itching	23 (57.5)	4 (10.0)
Diarrhea	11 (27.5)	3 (7.5)
Liver enzyme abnormality	6 (15.0)	2 (5.0)
Nausea/vomit	5 (12.5)	2 (5.0)
Anorexia	5 (12.5)	0 (0)
Insomnia	2 (5.0)	0 (0)
Dizziness/weakness	3 (7.5)	1 (2.5)
Headache	2 (5.0)	1 (2.5)
Pneumonitis/pneumonia	2 (5.0)	1 (2.5)
Creatine increased	1 (2.5)	1 (2.5)

BALF, bronchoalveolar lavage fluid.